UK based drug discovery, development and commercialisation company Synairgen plc appointed Theodora Harold as the Non-Executive Director of the Company and Chair of the Audit Committee, effective immediately. With over twenty years of experience in the field of biotechnology and is currently the CEO of Crescendo Biologics Ltd. 

Prior to this, she founded management teams at both PsiOxus Therapeutics and Mission Therapeutics Ltd. Harold also held directorships and/or partnerships at Orlixus Ltd, Dreadnought Ltd, Cambridge Consultancy Services Ltd and Chronos Therapeutics Ltd where she served as non-executive director. With her previous experience she will be involved with the company’s current focus on developing SNG001 (inhaled interferon beta) for COVID-19 antiviral treatment meant for direct use into the lungs. 

Commenting on the appointment, Simon Shaw, Chairperson, Synairgen, said, “I am delighted to have Theodora joining the Board at this pivotal point for Synairgen. Her breadth and depth experience brings a welcome new perspective to the Board and her expertise in the life sciences and biotech industries will be of great value.”

“Synairgen is at an important stage in its growth as it looks to expand access of this innovative inhaled interferon beta treatment to patients, particularly those severely ill with COVID-19. This is an exciting time to join the Synairgen team, and I look forward to working with Simon and the Board in pursuing a successful future for the Company,” said newly appointed  Theodora Harold.